Trifolium Bio-B (02197) initiates Phase I clinical trial of respiratory syncytial virus (RSV) + human metapneumovirus (hMPV) parainfluenza virus type 3 (PIV3) respiratory co-vaccine candidate product.

Financial News from Zhitong APPClover Biopharmaceuticals (02197) announced that the Phase I clinical trial of the respiratory combination vaccines SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) has successfully enrolled its first group of subjects. The fusion pre-fusion stabilized F (PreF) trimer subunit vaccine antigens of these vaccine candidates are based on Clover Biopharmaceuticals' protein trimerization vaccine technology platform.